Health technology assessment of belimumab: a new monoclonal antibody for the treatment of systemic lupus erythematosus

Maria Lucia Specchia, Chiara Cadeddu, Maria Luisa Di Pietro, Walter Ricciardi, Chiara De Waure, Francesco Di Nardo, Silvio Capizzi, Maria Assunta Veneziano, Maria Daniela Gliubizzi, Antonella Sferrazza, Nicola Nicolotti, Giuseppe La Torre, Maria Rosaria Gualano, Andrea Doria, Giuseppe Turchetti, Lara Pippo, Luca Iaccarino, Francesca Pierotti, Ilaria Palla, Rolando Porcasi

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Systemic lupus erythematosus (SLE) is treated with anti-inflammatory and immunosuppressive drugs and off-label biologics. Belimumab is the first biologic approved after 50 years as an add-on therapy for active disease. This paper summarizes a health technology assessment performed in Italy.
Original languageEnglish
Pages (from-to)704207-704215
Number of pages9
JournalBioMed Research International
Volume2014
DOIs
Publication statusPublished - 2014

Keywords

  • HTA
  • Lupus

Fingerprint

Dive into the research topics of 'Health technology assessment of belimumab: a new monoclonal antibody for the treatment of systemic lupus erythematosus'. Together they form a unique fingerprint.

Cite this